Narcotic Analgesics

Walmart Offers Unique Opioid Disposal Solution With DisposeRx

By January 17, 2018

Packets contain a crosslinking polymer blend that, when added to the pill bottle with warm water, sequester any form of prescription drugs - including powders, pills, tablets, capsules, liquids or patches - into a non-divertible and biodegradable gel.

Comprehensive Examination of Impact of Tamper-Resistant Oxycodone

January 12, 2018

The researchers observed reduced sales of higher strengths of controlled-release oxycodone and increased sales of other oxycodone formulations.

New Guidelines Published on Opioid Use in Refractory RLS Treatment

By January 09, 2018

Although the research found opioid use to have a favorable risk-benefit ratio, other avenues of treatment should be considered before opioid prescription including addressing iron stores and combination therapy.

Best Practices for Improving Opioid Tapering Discussions Identified

January 02, 2018

Patients should understand individualized reasons for tapering, know their providers will not abandon them

Topical Analgesic Use Improves Pain, Opioid Discontinuation in Study

By December 27, 2017

The analysis evaluated changes in opioid use, other concurrrent medication use, and pain severity and interference in opioid-experienced patients

Arymo ER Tentatively Approved for Expanded Abuse Deterrence Claim

By December 15, 2017

The abuse deterrent data was not included in the original New Drug Application (NDA) label at time of approval due to exclusivity granted to another company.

Urine Drug Monitoring Recommendations for Opioid Use in Chronic Pain

By December 15, 2017

For low-risk patient, testing should be conducted at least yearly, for those at moderate risk, ≥2 times a year, and for those at high risk, ≥3 times a year.

Do Pre-Op Cholesterol Levels Impact Post-Op Pain Outcomes?

December 13, 2017

The researchers observed a weak, but significant, positive correlation between total cholesterol and numeric rating scale scores on post operative days 0 and 1.

Hospital Discharge Prescription Opioid Volume Varies

December 13, 2017

Overall, 35.7% of patients used no opioids in the 24 hours before discharge; 45.6% of these patients were prescribed opioids at hospital discharge.

Provider Perspectives Assessed on Medical Marijuana Use for Pediatric Cancer

December 12, 2017

Of the 288 responses, the researchers found that one-third of respondents were legally eligible to certify (ETC). Thirty percent of providers reported receiving at least 1 request for MM in the previous month.

FDA to Review Novel Buprenorphine SL Spray for Acute Pain

By December 06, 2017

Compared to other commonly used opioids, buprenorphine offers a ceiling effect for respiratory depression and less abuse potential, less cognitive impairment, and less constipation.

ASHP: Revised Standards can Build Framework for Opioid Stewardship

December 06, 2017

The new and revised standards from The Joint Commission were published in July 2017 to address some of the issues associated with over-prescribing and lack of monitoring.

Certain Drug Classes Tied to Less Frequent Driving Impairment Warnings

By December 01, 2017

More than two-thirds (85%) of those on sedatives and narcotics reported being counseled by a provider on the possibility of impaired driving.

New Treatment Option for Opioid Use Disorder Gets Approval

By December 01, 2017

Sublocade should be used as part of a complete treatment program that includes counseling and psychosocial support.

Naloxone Effectiveness Compared by Route of Administration

November 28, 2017

Higher-concentration intranasal naloxone (2mg/mL) seems to have efficacy similar to that of intramuscular naloxone for reversal of opioid overdose, with no difference in adverse events.

FDA Grants Priority Review to Lofexidine for Opioid Withdrawal Management

By November 21, 2017

Lofexidine, an oral tablet, is a selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine.

Treatments Compared for Prevention of Opioid Relapse

November 20, 2017

Difficulty initiating XR-NTX accounts for difference in relapse rates in intent-to-treat population

Codeine Rxs Down After FDA Investigation on Opioid Prescribing to Children

November 17, 2017

But 1 in 20 patients undergoing tonsillectomy and/or adenoidectomy still prescribed codeine

Device to Help Reduce Symptoms of Opioid Withdrawal Gets FDA Approval

By November 16, 2017

The FDA approval is supported by a single-arm clinical study of 73 patients undergoing opioid physical withdrawal.

Opioid Rx Patterns Assessed Post-Hysterectomy

November 10, 2017

Patients reported using about half of the opioids prescribed, with a median excess of 110 oral morphine equivalents.

Xtampza ER Labeling Updated With Oral Abuse Deterrent Claim

By November 09, 2017

Xtampza ER (oxycodone extended-release) is an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Cannabidiol Products Sold Online Often Have Inaccurate Labeling

November 08, 2017

The researchers found that the observed CBD concentration varied from 0.1 to 655.27 mg/mL (median, 9.45 mg/mL); the median labeled concentration was 15 mg/mL.

Non-Opioid Meds Compared to Opioids for Acute Extremity Pain

By November 07, 2017

The authors concluded, "The findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture."

NDA Submitted for Olinvo to Treat Moderate to Severe Acute Pain

By November 02, 2017

Olinvo is a next generation IV analgesic for the management of moderate-to-severe acute pain in the hospital and similar settings and has been granted Breakthrough Therapy designation by the FDA.

FDA Advisory Committees Reach Decision on Opioid Use Disorder Tx

By November 01, 2017

A Phase 3 study found that 300mg and 100mg doses of RBP-6000 had significantly greater abstinence rates when compared with placebo; 300mg/300mg: 41.3%; 300mg/100mg: 42.7%; placebo: 5.0%.

Illicit Fentanyl Major Driver of Opioid Overdose Deaths in U.S.

November 01, 2017

Data from 10 states participating in the CDC's Enhanced State Opioid Overdose Surveillance program was used to describe opioid overdose deaths from July through December 2016 that tested positive for fentanyl; fentanyl analogs; or U-47700, an illicit synthetic opioid.

Opioid Epidemic Declared Public Health Emergency

By October 27, 2017

Unlike a national emergency, which is what Mr. Trump has referred to the epidemic has, a public health emergency does not involved the release of any federal funds.

Walgreens Takes Steps to Make Life-Saving Drug More Accessible

By October 26, 2017

Narcan Nasal Spray, an opioid antagonist, is indicated for the reversal of known or suspected opioid overdose, including respiratory and/or central nervous system (CNS) depression.

Opioid Alternative Tx for Surgical Site Granted Fast Track Status

By October 26, 2017

In bunionectomy and hernia repair HTX-011 (60mg and 300mg, respectively) was found to significantly reduced pain through 72 hours compared to placebo and bupivacaine (P=0.0003 and P=0.0106).

DEA Sets Date to Collection Unwanted Rx Drugs From Public

October 25, 2017

Last April, 450 tons of prescription drugs were collected at almost 5,500 sites operated by the DEA and more than 4,200 state and local law enforcement partners.